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Abstract 
Objective: Pelvic exenteration requires complete resection of the tumor with negative margins to 
be considered a curative surgery. The purpose of this review is to assess the optimal preoperative  
evaluation and surgical approach in patients with recurrent cervical cancer to increase the 
chances of achieving a curative surgery with decreased morbidity and mortality in the era of 
concurrent chemoradiotherapy.
Methods: Review of English publications pertaining to cervical cancer within the last 25 years 
were included using PubMed and Cochrane Library searches. 
Results: Modern imaging (MRI and PET-CT) does not accurately identify local extension of 
microscopic disease and is inadequate for preoperative planning of extent of resection. Today, 
only half of pelvic exenteration procedures obtain uninvolved surgical margins.  
Conclusion: Clear margins are required for curative pelvic exenterations, but are poorly 
predictable by pre-operative assessment. More extensive surgery, i.e. the infra-elevator 
exenteration with vulvectomy, is a logical surgical choice to increase the rate of clear margins 
and to improve patient survival following surgery for recurrent cervical carcinoma.  
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INTRODUCTION : 
Cervical cancer represents a major public health burden with 529 000 new diagnoses and 275 
000 deaths annually worldwide [1]. Treatment options differ depending on the extent of tumor 
spread at the time of diagnosis. Early cervical cancers, defined as   IB1 by the International 
Federation of Gynecology and Obstetrics (FIGO) classification [2], can be treated by surgery 
(radical hysterectomy and lymphadenectomy) and/or radiation therapy with equivalent results in 
terms of relapse-free and overall survival [3]. For cases of locally advanced cervical cancer, 
FIGO IB2, concomitant chemoradiotherapy is recommended based on the results of clinical trials 
from the 1990s [4-7]. Today concomitant chemoradiotherapy is the primary treatment for 
approximately 70% of patients [8]. Despite local control and a prolongation of disease-free 
survival, an estimated 20-30% of patients develop recurrent disease within the radiation field. 
The majority of recurrences occur 18-24 months following initial treatment. Risk of recurrence 
increases with FIGO stage and is estimated to be 10% for stage IB patients, 17% for IIA, 23% 
for IIB, 42% for III and 74% for IV [9]. 
When local recurrence occurs, treatment options are limited due to the frequent use of pelvic 
irradation for primary cervical cancer. Reirradation of the same anatomic site is contraindicated, 
and chemotherapy is ineffective at controlling tumors located within the previously irradiated 
tissue that tends to be less vascularized [10, 11]. A recent Cochrane review was unable to 
compare the effectiveness of medical (radiotherapy and/or chemotherapy) versus surgical  
treatment for recurrent cervical cancer given the absence of randomised controlled trials [12]. 
Surgical resection is often the only treatment option for disease recurrence but it is associated 
with a high rate of complications due to the fragility of the tissue after concomitant 
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radiochemotherapy [9]. Curative surgical resection of locally recurrent cervical cancer is pelvic 
exenteration with removal of neighboring organs such as bladder and rectum [9, 11, 13]. 
However, there is a lack of consensus regarding the optimal extent of the resection margins and 
whether the best chance of cure should include a pelvic exenteration with anterior, posterior 
and/or inferior exenterations. There is also no clear definition as to which patients should 
undergo curative versus palliative treatment. For example, lateral pelvic recurrences are 
considered eligible for resection by some teams, yet unresectable by others [14]. 
The goal of this review is to define the preoperative workup for recurret cervical cancer to guide 
the selection of patients for curative surgery, as well as the optimal extent of surgery in terms of 
morbidity and mortality. 
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MATERIALS AND METHODS : 
The literature was reviewed for articles published during the past 25 years using the 
following Medical Subject Headings (MeSH): pelvic exenteration, recurrent cervical cancer, 
cervical cancer treatment, radiotherapy and cervical cancer. All meta-analyses, systematic 
reviews and original articles written in english were reviewed. The following databases were 
searched:  
- Medline : PubMed (Internet portal of the National Library of Medicine)  
http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed 
-  The Cochrane library: Cochrane-database 'Cochrane Reviews' and 'Clinical Trials' 
http://www3.interscience.wiley.com/cgi-bin/ mrwhome/106568753/HOME 
DARE 
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RESULTS 
PRE-OPERATORY EVALUATION OF CERVICAL CANCER RECURRENCE : 
Evaluating the extent of recurrent tumor growth is important for proper patient management. 
Recurrent cervical cancer is classified as a central pelvic recurrence when the tumor is limited to 
the vagina, bladder, rectum and/or parametrium, and as a lateral pelvic recurrence when it 
spreads to the muscles and vasculature of the lateral pelvic wall. Local tumor extension needs to 
be accurately defined to guide proper surgical management. It is also important to eliminate the 
presence of metastatic tumor, which is considered to be an incurable progression of disease. 
Distant recurrent cervical cancer involves para-aortic, supra-clavicular or pulmonary lymph 
nodes in 81%, 7%, and 21% of cases respectively [15]. 
Preoperative evaluation of the extent of cervical cancer spread traditionally involved clinical 
examination of the patient under general anaesthesia with endoscopic evaluation of the bladder 
and/or rectum as required. Magnetic resonance imaging (MRI) is now the preferred modality to 
evaluate the size of the tumor, and its relationship with neighboring organs (Table 1) [16]. 
Compared to computed tomography (CT), MRI has a higher sensitivity for detecting spread to 
the bladder (75%), rectum (71%), parametrium (74%) and lymph nodes (60%). The specificity of 
MRI is generally comparable to CT, with the exception of bladder invasion which has been 
found to have a specificity of 91% by MRI and 73% by CT [17].  MRI can be used to predict 
uninvolved surgical margins with a sensitivty of 85% and a specificity of 52%, with a positive 
predictive value of 60% and a negative predictive value of 80% [18]. Improvements in the ability 
of imaging to detect tumor extension will allow for more detailed preoperative planning. The 
surgeon will be better equipped to determine if curative surgery is feasible and will increase the 
chances of achieving uninvolved surgical margins. Currently all radiologic modalities are limited 
by their poor sensitivity in picking up microscopic disease, as well as their poor specificity in 
distinguishing tumor from radiation-induced fibrosis.  
For the evaluation of distant metastases, positron emission tomography-computed tomography 
(PET-CT) is superior to MRI and CT [19]. PET-CT has been shown by Husain et al. to detect 
distant metastases with a sensitivity of 100% and a specificity of 73%, with a positive predictive 
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value of 55% and a negative predictive value of 100 % [20]. A meta-analysis of 1757 patients 
found that PET-CT has a sensitivity of 90% and a specificity of 99% in detecting distant 
metastases in cases of recurrent cervical cancer [21]. 
Currently the standard approach for evaluating patients with recurrent cervical cancer involves 
analyzing and correlating the findings from both MRI and PET-CT imaging. Combining the 
information provided by these two techniques allows for more precise evaluation of the size of 
the recurrence, the extent of invasion of adjacent structures and the presence of lymph node 
metastases (p= 0,041) [22]. Curative surgery requires complete tumor resection with uninvolved 
surgical margins and is a strong prognostic factor for postoperative survival. Imaging allows for 
better patient selection and planning of surgical procedures to increase the chances of a curative 
surgey, and to help avoid performing extensive surgeries, such as pelvic exenterations, for 
unresectable disease. In 1989 approximately 40% of pelvic exenterations were aborted 
intraoperatively due to unresectable disease [23]. 
There is minimal data regarding the accuracy of imaging in the preoperative evaluation of lymph 
node involvement because metastases to pelvic lymph nodes is a contraindication for curative 
pelvic exenterations. Preoperative imaging has been shown to detect nodal metastases with a 
sensitivity of 75% and a specificity of 52%, suggesting that patients should undergo lymph node 
dissection if there is any suspicion of involvement [18, 24]. While there are no precise 
recommendations in the literature, patients without preoperative evaluation of their lymph nodes 
should have them removed laparoscopically and evaluated intraoperatively in all cases, even if 
the patient received neoadjuvant radiation.  
SELECTION OF PATIENTS ELLIGIBLE FOR CURATIVE SURGERY : 
When Dr. Brunschwig first described the technique of pelvic exenteration in 1948, it was 
considered a palliative treatment to remove gastric and/or urinary fistulas with a survival rate of 
less than 20% at 5 years [25]. Today the goal of pelvic exenteration is curative, aiming to 
achieve complete tumor resection with margins that are free of microscopic disease. According 
to some studies, the survival rate at 5 years is now closer to 60% with an acceptable rate of 
postoperative morbidity (Tables 2 and 4). In patients with visceral or lymph node metastases, 
there is no proven benefit of attempting curative surgery. Pelvic exenterations are therefore 
reserved for isolated central recurrences or lateral pelvic recurrences that do not involve the 
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sciatic nerve, in patients whose general health and nutritional status permit such an extensive 
surgery [14, 26].  
PROGNOSTIC CRITERIA FOR ISOLATED PELVIC RECURRENCE OF CERVICAL 
CANCER : 
There are several prognostic factors that should be evaluated in patients with recurrent cervical 
cancer, that is limited to the pelvis, before considering a pelvic exenteration: 
1) Size of tumor recurrence - lesions measuring more than 5cm in diameter have been 
shown by some authors to have almost no chance of remission despite complete removal 
of the tumor with uninvolved surgical margins [9, 10]. 
2) Length of time between initial cancer treatment and the recurrence - Marnitz et al  
found a correlation between the length of time to recurrence and patient survival such that 
a recurrence at less than 2 years, between 2 to 5 years and more than 5 years after initial 
treatment is associated with a 5-year survival rate 16.8%,  28.0% and 83.2% respectively 
[10]. Recently, Chiantera et al also determined that a recurrence occuring more than two 
years after initial treatment is associated with better overall patient survival rates (p= 
0,012) [27]. The prognostic value of time to recurrence is still debated because some 
authors have found no association with survival [28, 29]. 
3) Histologic type of recurrence - squamous cell carcinomas are associated with a 
significantly worse prognosis than adenocarcinomas of the cervix (p= 0,003).  The poorer 
prognosis may be a reflection of the fact that perineural invasion is more frequently 
present in squamous cell carcinomas (p= 0,004) [30]. 
4) Presence of lymph node involvement at initial presentation - the prognostic value of 
lymph node involvement is controversial and has been evaluated in only a few studies. It 
has been found that patients presenting with lymph node metastases have a worse 
prognosis [31, 32]. Recently this notion was challenged by Been et al in a study that 
showed no significant difference in survival rates [33].  
The size of the cervical cancer recurrence, the interval of time to recurrence and the histologic 
type of the tumor are important elements to consider preoperatively before offering patients a 
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potentially curative pelvic exenteration surgery. The age of the patient has not been found to 
influence overall, or disease-free, survival rates [34, 35].   
Postoperatively, histopathologic evaluation of the tumor provides additional prognostic 
information.  
1) Metastasis to mesorectal lymph nodes is significantly associated with a shorter median 
disease-free survival interval of 2.4 months, compared to 7.3 months in patients without 
mesorectal lymph node involvement (p= 0,005) [27, 36, 37]. 
2) Lymphovascular space invasion (LVSI) is an independent prognostic factor which 
negatively impacted overall survival [38]. Assessing the presence of vascular emboli on 
pretherapeutic biopsies could facilitate the selection of patients eligible for curative 
pelvic exenterations [39]. 
3) Surgical resection margins involved by invasive carcinoma is a major significant and 
independent prognostic factor associated with decreased survival of patients [23]. 
Postoperative survival at two years drops from 55.2% with uninvolved margins to 10.2% 
with positive margins (p= 0,0057) [10]. Some authors have found that the survival rate in 
patients with positive margins falls to 0% after three years [28, 40]. 
In conclusion, patient survival depends on numerous pre and postoperative factors of which only 
one is modifiable, the achievement of surgical margins that are confirmed to be uninvolved by 
invasive carcinoma after histologic evaluation.  
DISEASE-FREE AND OVERALL SURVIVAL IN PATIENTS FOLLOWING 
EXENTERATION FOR RECURRENT CERVICAL CANCER : 
Since the initially reported cases of exenteration in 1948, the rate of five-year survival has 
increased considerably from 20% in the 1970s to 64% in recent series where patients were better 
selected.   
In 1989, based on the analysis of a large series of cervical cancer patients treated by pelvic 
exenteration,  Shingelton et al estimated that the median delay to cancer recurrence was 12 
months, with death typically ensuing 3 to 5 months later [23]. More recent studies, in the era of 
concurrent chemoradiotherapy, have found that the median time interval to recurrence is 6.1 to 7 
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months [33, 36]. The relatively short time interval to cancer recurrence highlights the importance 
of assessing prognostic factors preoperatively to select patients that are best suited for 
exenterations.  
Cervical cancer recurs locally, in the pelvis or perineum, in approximately 35-60% of relapsed 
patients. While 20-40% of patients with recurrent disease present with distant metastases mainly 
involving the lungs, lymph nodes and bone. The tendancy towards local recurrence has not 
changed since the introduction of concomitant chemoradiotherapy. In 1999, a review of the 
literature by Estape et al found that the rate of local recurrence and distant metastases is 50-64% 
and 19% respectively [41]. Shingleton et al did not find an association between the type of 
exenteration and the type of recurrence (local vs distant) [23]. 
In general, for patients where exenteration is the final therapeutic option, studies have found an 
encouraging rate of survival. However it is difficult to compare the results of the different studies 
since there is a large heterogeneity with respect to the type of procedure that was performed and 
the type of cancer that is being investigated (cervical, endometrial, vulvar or ovarian). Studies 
rarely focus uniquely on cervical cancer and even more rarely on cervical cancer recurrences. As 
shown in table 3, anterior, posterior, total, supra or infralevator exenterations are all described in 
the literature but authors rarely explain how or why a given procedure was chosen. Since 
uninvolved surgical margins is such an important prognostic factor that is potentially modifiable, 
it would be useful to understand the reasons surgeons opt for one procedure over another.
DIFFERENT TYPES OF PELVIC EXENTERATIONS : 
Radical pelvic exenteration was initially described by Brunschwig as a palliative procedure for 
central pelvic recurrences of cervical cancer. Recurrences that are limited to the cervix and/or 
upper vagina are amenable to a total hysterectomy with pelvic lymph node dissection. He 
defined three additional categories of local disease recurrence and suggested the following types 
of resection [25] : 
4) Anterior: With invasion of the bladder it is recommended that the entire bladder, uterus 
and vagina be removed. 
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5) Posterior: Invasion of the rectum is amenable to complete excision of the vagina, uterus 
and involved segment of bowel. 
6) Total: Invasion of the bladder and rectum requires removal of bladder, vagina, uterus and 
rectum.  
Lateral pelvic extension was considered a contraindication to surgical exenteration for a long 
time because it was not possible to achieve tumor-free surgical margins [28]. In 2008, Höckel et 
al demonstrated that patients with recurrent cervical cancer involving the pelvic side wall can 
benefit from a laterally extended endopelvic resection (LEER) [32]. To date, their series includes 
91 patients with a overall survival rate of 61% at 5 years [14]. The LEER technique involves the 
resection of some, or all, of the following lateral pelvic structures : obturator internus muscle, 
pubococcygeus muscle, iliococcygeus muscle, coccygeus muscle, internal iliac vessels and the 
lumbosacral nerve plexus. The only contraindication to the LEER procedure is involvement of 
the sciatic nerve [26, 42]. 
Pelvic exenterations are now subclassified into type I (supralevator), type II (infralevator), and 
type III (infralevator with vulvectomy) exenterations based on the extent of surgical resection. 
The extent of tumor extension dictates the type of exenteration that is required to obtain 
uninvolved surgical margins. A study by Magrina et al found that there was no significant 
difference in patient survival between the three types of exenteration, provided that no cancer 
was present at the resection margins [43]. Recently, these results were confirmed by Berek et al
et Yoo et al [28, 36]. Currently, a type III resection is feasible for any recurrence but is 
preferentially performed in patients with a recurrent lesion larger than 5cm or one that has 
invaded the anal canal, the lower part of the vagina and/or the vulva [43]. 
Given the strong prognostic significance of uninvolved surgical margins, several pre and 
intraoperative evaluations are performed, such as preoperative imaging to select patients with 
resectable lesions, intraoperative exploration to ensure complete surgical removal of all 
macroscopically visible tumor and intraoperative evaluation of the status of surgical resection 
margins. Despite these measures, 7-35% of exenterations performed with a curative intent, are 
found to have tumor present at the surgical resection margin after thorough pathological 
evaluation (Table 3). To reduce this risk, a type III exenteration can be proposed to patients. 
With the improvement of perineal and pelvic reconstruction techniques, the rate of intra and 
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postoperative complications is reasonable (Table 4) and the quality of life is comparable for all 
types of exenterations. 
MORBIDITY AND MORTALITY ASSOCIATED WITH PELVIC EXENTERATIONS : 
Pelvic exenterations are complex surgeries that are associated with a significant risk of 
morbidity. Resection of previously irradiated pelvic tissue leaves a large cavity that is prone to 
perineal leaking, poor primary wound healing and complications secondary to the obstruction of 
the ureters or bowel.   
The rate of early postoperative complications (within 30 days of the surgery) varies from 16-
71%. One of the most frequent complications is gastrointestinal fistulas with connections to the 
skin, urinary system or vagina. Other common complications include blood clots and leaking 
anastomoses. There are two main factors influencing the rate of early complications: 
preoperative radiation-induced tissue damage and the length of the operation [44]. The rate of 
late postoperative complications (occuring more than 30 days after surgery) ranges from 36-
61%. Late complications include enterocutaneous and vaginal fistulas, ureteral obstruction, 
bowel obstruction and pyelonephritis. These complications arise secondary to postoperative 
adhesions, tumor recurrence and urinary tract infections precipitated by self-catheterization [36]. 
Magrina et al did not find a significant difference between the rate of early or late complications 
and length of hospital stay among the different types of exanterations [43]. These findings were 
recently confirmed by Yoo et al [36]. The mortality asscoiated with intra and postoperative 
complications varies from 0-12% depending on the study (Table 4). Benn et al found that 
survival time is significantly reduced in patients that develop postoperative complications that 
are considered complex (p=0,03) [33]. 
The morbidity associated with type III exanterations has been shown to be reduced in patients 
with pelvic floor reconstructions. The rate of bowel obstruction, pelvic abscess and fistula 
formation is decreased when musculocutaneous flaps are used to fill the pelvis for vaginal 
reconstructions [24, 44]. Miller et al, found that filling of the pelvic cavity led to a decrease in 
the rate of fistula formation from 16 to 4.5% [45].
The rates of postoperative complications vary widely in the literature. Dindo et al proposed a 
grading system for the classification of complications as a comparison tool, but few authors have 
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adopted it [46]. Certain severe complications appear to occur significantly less often when pelvic 
reconstruction is performed, which is an argument in favor of type III exanterations. Type III 
exanterations may also increase the probability of tumor-free resection margins. 
RECONSTRUCTION : 
Various techniques for urinary, gastrointestinal and pelvic reconstruction have been developed 
for the different types of pelvic exenteration to improve the quality of life of patients [24, 44]. 
Urinary reconstruction : 
The technique used for urinary reconstruction depends on the preference of the surgeon and the 
anatomical condition of the pelvis following radiation therapy. A cutaneous ureterostomy is the 
least technically challenging approach, but it has become obsolete due to problems with the 
required equipment [47]. Currently, two techniques are performed : 
- Bricker non-continent ileal conduit urinary diversion involves anastomosing the ureters 
to a 15-20cm segment of unirradiated ileum that opens into a cutaneous stoma of the right 
iliac fossa 
- Miami Pouch continent ileocolic urinary diversion consists of anastomosing the ureters 
to a low-pressure reservoir using distal ileum, right colon or proximal transverse colon. A 
high pressure valve at the skin’s surface helps avoid incontinence. Rome, Indiana and 
Mainz 1 and 2 are all modified version of the Miami pouch. 
The major early postoperative complications are similar for both types of urinary reconstruction, 
and are primarily ureteral and gastrointenstinal anastomotic leaks. Goldberg et al described a 
complication rate of approximately 14% [48]. Houvenaeghel et al found that preoperative 
radiation increases the risk of postoperative complications and they suggest using a nonirradiated 
segment of bowel for the conduit to reduce this risk [47]. The main late postoperative 
complications are urinary tract infections and ureteral obstruction in 19 and 22% of cases, and 
are more frequently associated with continent diversions [49].  
There is no consensus as to which technique of urinary diversion should be performed. The 
Miami technique is appealing because it provides continence, but it can lead to other 
complications (catheterization difficulties 19% to 33% of cases [58, 59]) that negatively affect 
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the patient’s quality of life, which is why the non-continent Bricker approach is still an important 
alternative.  
A newer surgical technique was developed in which a segment of ileum is used to construct an 
orthotopic bladder, which avoids the need for a stoma and was hoped to increase the patient’s 
quality of life. This technique has a 50% rate of continence with a complication rate of 12.5%, 
compared to a complication rate of 2.9% for “standard” diversions [50]. This technique is rarely 
performed and is reserved for type I or II exenterations. So far it has not been shown to improve 
quality of life and thus should not be used as an argument against a type III exenteration. 
Gastrointestinal reconstruction :   
The standard reconstruction of rectal resections during pelvic exenterations is a definitive left-
sided colostomy. Direct anastomoses are preferable in terms of quality of life, but despite 
advances that facilitate this procedure, such as automatic suturing devices, this technique is 
associated with a high rate of major complications which is thought to be related to prior pelvic 
irradiation. Failure of the anastomosis is the most common complication, even in patients with 
proximal protective stomas [49, 51]. A recent study by Chiantera et al found that the 
complication rate increases from 14.5 to 20.4% when a colostomy reversal is performed [50]. In 
addition, Goldberg et al suggest that this technique should be avoided based on the finding that 
45% of their patients suffered from early tumor recurrence at the site of colorectal anastomosis 
[48]. Currently there is no accepted technique for colostomy reversal in patients undergoing 
pelvic exenterration for recurrent cervical cancer.
Vaginal and Perineal Reconstruction : 
Several different techniques have been developed for vaginal and perineal reconstruction [24, 
44]. As previously discussed, pelvic reconstruction reduces the risk of postoperative morbidity 
by filling the cavity that is created during pelvic exenteration and lowering the incidence of 
gastrointestinal fistulas and obstruction. It can also improve quality of life by restoring female 
body image.  For pelvic exenterations without perineal resections, there are two main techniques 
for vaginal reconstruction: 
- A pedicle graft of greater omentum, using either of the gastroepiploic arteries, can be 
introduced into the pelvis for vaginal reconstruction. To achieve a tubular shape the 
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tissue is placed around an inflatable device that is fixed to the vulvar vestibule. This is 
a simple surgical technique associated with a 35% risk of vaginal stenosis [52]. 
7) Bowel neocolpoplasty involves using a portion of the sigmoid or caecum to 
reconstruct the vagina. The segment of bowel that is used depends on the field of 
previous irradiation. The main complication of this technique is diversion colitis which 
can lead to frequent discharge requiring vaginal irrigation [53]. 
The most reliable techniques for pelvic exenterations with perineal resections involve 
musculocutaneous flaps that fill the pelvic cavity and allow for vaginal reconstruction when 
necessary. Currently, two main techniques are practiced: 
8) Gracilis flaps were the first reconstruction to be described and are associated with a 
rate of skin paddle necrosis that varies from 14-25% depending on the study [54]. 
When vaginal reconstruction is desired, bilateral gracilis flaps are used [55].  
9) A pedicled vertical (VRAM) and transverse (TRAM) rectus abdominis myocutaneous 
flap are approaches with several advantages due to the vascular reliability of the 
inferior epigastric artery. Houvenaeghel et al described only one case of necrosis 
among twenty patients that underwent the procedure [56]. Additionally, Soper et al 
found that only 12% of patients developed vaginal strictures or stenosis [57]. I realize 
you described vascular stenosis but I did not see any mention of vascular stenosis in 
reference 66 but they did describe a 12% rate of vaginal stenosis. A rectus 
myocutaneous flap is larger than a gracilis, which permits easier vaginal 
reconstruction using a single flap. The disadvantage of this technique is that it creates 
an abdominal wall weakness with 6-10% of patients developing incisional hernias 
[44]. 
10) Of note, free flaps anastomosed to iliac vessels have been described using 
abdominal or latissimus dorsi muscles, but this requires significant surgical experience 
[44]. 
In 1996, a study found that 95% of patients were satisfied with the vaginal reconstruction even 
though only 47% of them were sexually active [58]. Similarly, Goldberg et al described the rate 
of satisfaction and sexual activity as 85% and 56% respectively [48]. 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
In general, the improvement in reconstruction techniques allows for type 3 exenterations that do 
not significantly alter the quality of life of patients. Unfortunately, colorectal anastomoses for 
gastrointestinal reconstruction are associated with a risk of morbidity that is too significant to be 
used regularly. Currently there is not enough evidence about patient outcome following ileal 
bladder reconstruction following type 3 exenterations. In contrast, pelvic reconstruction is 
associated with high levels of patient satisfaction [43].   
NEOADJUVANT AND ADJUVANT TREATMENT : 
The efficacy of neoadjuvant and adjuvant treatments are currently being evaluated to improve 
patient outcome.  
Intraoperative Radiation Therapy: 
High dose intraoperative radiation therapy was initially used when the margins of a laterally 
extended endopelvic resection were found to be involved with cancer by intraoperative 
pathologic assessment. This technique was shown to increase patient 5-year survival from 11 to 
42% [59]. It was also found to cause significant gastrointestinal and nervous system toxicity in 
25% and 30% of patients respectively [60]. 
Neoadjuvant Chemotherapy: 
A recent study by Landoni et al investigated the role of preoperative chemotherapy for patients 
presenting with poor prognostic factors such as tumor size larger than five centimeters, lateral 
pelvic extention of tumor and recurrence less than a year after initial treatment. The 
chemotherapy was prescribed as three cycles of Taxol, Ifosfamide and Cyclophosphamide. 
While the study only involved 31 patients, the results were encouraging with tumor shrinkage in 
61% of patients with a rate of uninvolved margins, complications, overall and disease-free 
survival comparable to patients who initially presented with a better prognosis [61].  
Complete surgical excision remains the gold standard treatment for cervical cancer recurrence. 
As not all patients are eligible for curative surgery, it is hoped that the trials investigating 
radiation and chemotherapy will lead to improved patient care.  
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CONCLUSION :  
Pelvic exenteration is a complex surgical procedure that remains the sole curative therapeutic 
option for recurrent cervical cancer in patients that received prior radiation therapy. Preoperative 
patient selection requires MRI and PET-CT imaging that does not demonstrate any evidence of 
tumor metastasis. There is a lot of heterogeneity in the design of studies in the literature in terms 
of patient selection (exenteration for cervical, endometrial, vulvar and/or vaginal cancer 
recurrence), procedure type (anterior, posterior or total, supra or infralevator exenterations with 
or without perineal resection) and the recording of postoperative complications (lack of 
standardized classification). Two large studies from 1989 and 1997 found that the type and level 
of resection did not influence patient survival [23, 43]. Many large studies have found that the 
strongest independent and modifiable prognostic risk factor is final surgical margins that are free 
of cancer. Since the preoperative workup does not allow for accurate prediction of postoperative 
margin status, it is prudent to offer type 3 exenterations (infralevator with perineal resection) to 
increase the chance of uninvoled surgical margins, and thus improve patient survival, in cases of  
recurrent cervical cancer following pelvic radiation therapy with or without chemotherapy, 
especially if quality of life can be improved by using reconstructive techniques that protect 
against postoperative complications such as occlusion, fistulas and pelvic abscesses.  
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Table 1 : Performance of MRI in detecting extent of pelvic tumor invasion and presence of nodal 
metastases in patients with primary and/or recurrent cervical cancer.  
ORGAN 
EVALUATED 
 BLADDER RECTUM 
LATERAL PELVIC 
COMPARTMENT 
NODAL 
METASTASES 
Popovitch 
19
Bipat 
17
Rockall 
16
Forner 
18
Donati 
20
Se 
Sp 
PPV 
NPV 
Se 
Sp 
PPV 
NPV 
Se 
Sp 
PPV 
NPV 
Se 
Sp 
PPV 
NPV 
Se 
Sp 
PPV 
NPV 
67% 
93% 
75% 
91% 
100% 
88% 
100% 
7% 
NA 
87% 
93-100% 
91-100% 
90% 
67% 
93% 
71% 
100% 
91% 
100% 
17% 
NA 
75-81% 
97% 
92% 
89-91% 
80% 
76% 
50% 
100% 
NA 
NA 
75% 
65% 
65% 
75% 
75-87% 
94-97% 
75-87% 
94-97% 
NA 
60% 
NA 
75% 
52% 
56% 
69% 
NA 
Se : sensitivity, Sp : specificity, PPV : positive predictive value, NPV : negative predictive value, NA : Not 
available 
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Table 2 : Overview of patient survival and site of recurrence following pelvic exenteration.   
Authors Date Range 
of Cases 
Analyzed  
Number of 
Curative 
Pelvectomies 
Average (a) 
or 
Median (m) 
Duration of 
Patient 
Follow-up 
(months)  
Average (a) 
or Median (m) 
Time to 
Recurrence 
(months)   
Average (a) 
or Median 
(m) Time to 
Death 
(Months) 
Survival Rate for 
Patients Following 
Exenterations for 
Gynecologic 
Malignancies 
Survival Rate for 
Patients Following 
Exenterations for 
Cervical Cancer 
  
Site of 
recurrence  
Shingleton 
23
September 
1969 to 
January 
1986 
NA NA m: 9.6 - 12  NA OS : 50% at 5 years Idem 64% pelvic 
12% lymph 
nodes 
9% abdomen 
7% lung 
Berek 
28
1956- 2001 75 (100%) a : 45.5 
m: 50 
NA NA NA OS : 57% at 3 years 
and 54% at 5 years 
NA 
Goldberg 
42
January 
1987 to 
December 
2003 
103 (100%) NA NA NA OS : 47 % at 5 years OS : 48% at 5 years For the 6 
patients alive at  
5 years: 
2 lung 
1 liver 
3 para-aortic 
lymph nodes 
Maggioni 
43
June 1996 
to 
April 2007 
99 (97%) m: 22.3 
(1.6-117) 
NA NA OS at time of median 
follow-up : 34% 
OS at time of 
median follow-up : 
52% 
NR 
Been 
33
January 
1990 to 
August 
2009 
47 (87%) m: 12.5  
(0-158) 
m: 7 
(0-33) 
m: 29  
(12-42) 
OS : 44% at 2 years 
OS : 34% at 5 years 
NA 10% distant 
metastases  
31% 
locoregional 
recurrence 
(vagina, 
perineum, 
abdomen) 
Vergote 
44
June 1999 
to 
April 2010 
36 (100%) m: 78 m: 11 
(3-58) 
NA OS : 44% and DSS : 
52% at 5 years  
OS : 38% and DSS : 
44% at  5 years 
35% local 
recurrence 
Baiocchi 
45
January 
2000 to 
September 
2010 
107 (100%) m: 23.7 
(1-122) 
NA NA OS : 49.9% at 2 
years 
OS : 27.4% and 
DSS : 41.1% at 5 
years 
OS : 24.7% at 5 
years 
NA 
Yoo 
36
January 
2001 to 
April 2011 
61 (100%) m: 22 
(1-60) 
m: 6.1  
(0.7-7.8) 
m: 6.5  
(0.1-58.2) 
OS : 56% and DFS : 
49% 
at 5 years 
Idem 28 distant 
metastases 
(lung, liver, 
bone, lymph 
node) 
8 local 
recurrences 
Schmidt 
46
NA 156 (73.5%) a: 45  
m: 17  
NA NA OS : 41% 
DFS : 61% at 5 years 
OS : 64% at 5 years NA 
Tanaka 
47
August 
2002 to 
August 
2011 
12 (100%) m: 22 
(3-116) 
NA NA SG : 42.2% at 5 
years 
NA NA 
Chiantera 
48
1998-2011 223 (97%) m: 68 a: 13.4  a: 19 OS: 38% at 5 years NA NA 
OS : Overall Survival, DSS : Disease Specific Survival, DFS : Disease Free Survival. 
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Table 3 : Summary of recent studies on pelvic exenterations 
Author and 
Year 
Published 
Location of 
Cancer [Number 
(%)] 
Number (%) of 
Patients That 
Received 
Preoperative 
Radiation 
Number (%) 
of Curative 
Surgeries 
Number (%) 
of Palliative 
Surgeries 
Number (%) of Types 
of Exenteration 
Number (%) 
Patients With 
Cancer Present at 
Surgical Resection 
Margins   
 Time to Cancer 
Recurrence 
(Months) Before 
Exenteration 
Berek 
2005 
28
Cervix= 53 
(70%) 
Vagina= 14 
Endometrium= 8 
NR 75 (100%) 0 Total : 46 (61%) 
Anteroir : 23 (31%) 
Posterior : 6 (8%) 
or 67 (89%) 
supralevator 
     8 (11%) 
infralevator 
9 (12%) Average : 45.5 
Golberg 
2006 
44  
Cervix= 95 
(97%) 
Endometrium= 2 
Vulva= 1 
Rectum= 5 
98 (95%) 98 (95%) 0 Total : 98 (100%) NR NR 
Maggioni 
2009 
45
Cervix= 62 
(61%) 
Vagina= 21 
Vulva= 9 
Endometrium= 9 
Ovary= 4 
99 (97%) 99 (97%) 2 (3%) Total : 48 (45%) 
Anterior : 53 (49%) 
Posterior : 6 (6%) 
or 21 (20%) 
supralevator and 85 
(80%) 
infralevator 
7 (7%) Median : 16.7  
Been 2011 
33
Cervix= 40 
(74%) 
Vulva=9 Vagina= 
5 
47 (87%) 52 (96%) 2 (4%) Total : 36 (67%) 
Anterior : 13 (25%) 
Posterior : 5 (10%) 
7 (13%) Median : 32  
McLean 
2011 
46
Cervix= 29 
(66%) 
Vulva= 4 
Vagina= 5 
Endometrium= 6 
44 (100%) 44 (100%) 0 Total : 34 (77%) 
Anterior : 5 (11.5%) 
Posterior : 5 (11.5%) 
3 (7%) Average : 74  
Vergote 
2012 
47
Cervix= 18 
(50%) of which 
17 were 
recurrences 
Endometrium= 9 
Vagina= 8 
Ovary= 1 
32 (89%) ovarall 
and 17 (100%) 
Of recurrences 
36 (100%) 0 Total : 15 (88%) 
Anterior : 2 (12%) for 
reccurent cervical 
cancer of which 11 
(65%) supralevator 
6 (35%) infralevator 
6 (16%) Median : 34.8 
Baiocchi 
2012 
48
Cervix=73 (68%) 
of which  
69 were 
recurrences 
Endometrium= 
17 
Vagina=10 
Vulva= 7 
NR 107 (100%) 0 Total : 56 (52.3%) 
Anterior : 31 (29.3%) 
Posterior : 10 (9.3%) 
LEER : 10 (9.3%) 
8 (7.9%) Median : 18.8 
Yoo 2012 
36
Cervix= 61 
(100%) 
60 (98%) 61 (100%) 0 Total : 42 (69%) 
Anterior : 17 (28%) 
Posterior : 2 (3%) 
9 (14.7%) Median : 34.1 
Schmidt 
2012 
49
Cervix= 282 
(100%) 
 Of which 212 
were recurrences 
156 (73.5%) 106 (50%) 106 (50%) Total : 262 (93%) 
Anterior : 14 (5%) 
Posterior : 6 (2%) 
76 (36%) Median : 18 
Tanaka 
2013 
50
Cervix= 12 
(100%) 
Of which 10 were 
recurrences 
10 (100%) of 
recurrences 
10 (100%) of 
recurrences 
0 Total : 3 (25%) 
Anterior : 8 (67%) 
Posterior : 1 (8%) 
4 (33%) NR 
Chiantera 
2014 
51
Cervix= 177 
(77%) 
Endometrium= 
28 
Vulva= 16 
Vagina= 9 
Of which 192 
were recurrences 
135 (70.3%) 223 (97%) 7 (3%) Total : 131 (57%) 
Anterior : 68 (29.6%) 
Posterior : 31 (13.5%) 
or 169 supralevator 
(73.5%) and 61 
infralevator (26.5%) 
64 (27.8%) Median : 14 
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Table 4 : Overview of major postoperative complications.
Authors Early 
Complications  
[number of cases 
(rate)] 
Type Late 
Complications 
[number of cases 
(rate)] 
Type Perioperative Death 
[number of cases (rate)] 
Berek 
28
NR NR NR 17 gastrointestinal fistulas  3 (4%) 
Goldberg 
47
NR NR NR NR 1 (0.9%) 
Maggioni 
48
48 (44.8%) NR 52 (48,5%) NR 0 
Benn 
33
27 (50%) 10 cardiorespiratory, 6 ileus, 1 ureteral 
obstruction 
33 (61%) 15 ileus, 11 ureteral, 15 hernias 0 
McLean 
49
NR 15 pelvic wall infections, 8 pelvic 
abscesses, 6 sepsis 
NR NR 1 (2%) 
Vergote 
50
21 (58%) 2 pelvic abscesses, 14 leaking stomas and 
sepsis 
18 (50%) 5 pyelonephritis 
14 fistulas 
1 (2%) 
Baiocchi 
51
57 (53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%) 8 fistulas, 9 occlusions, 16 
urinary obstructions  
13 (12%) 
Yoo 
36
10 (16%) 4 skin infections, 1 ileus 
5 fistulas, 3 wound dehiscences 
22 (36%) 10 fistulas (7 enterocutaneouss, 
2 rectovaginal, 1 
ureteroenteric) 
0 
Schmidt 
52
143 (51%) 42 rectovaginal fistulas, 20 pelvic 
abscesses, 10 pulmonary emboli 
NR NR 14 (5%) 
Tanaka 
53
10 (83%) 5 ileus, 3 leaking gastrointenstinal 
anastomoses 
NR NR 0 
Chiantera 
54
48 (21.3%) 23 sepsis, 15 cardiorespiratory, 39 wound 
dehiscences, 22 urinary, 29 
gastrointenstinal 
NR NR 7 (3%) 
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